AUSTRALASIA
Pfizer suffers setback in ENBREL battle
Pfizer suffered a setback last week in its Australian battle to protect ENBREL (etanercept), when its preliminary discovery application against Sandoz was dismissed by Justice Burley in the Federal...
Pfizer suffered a setback last week in its Australian battle to protect ENBREL (etanercept), when its preliminary discovery application...
Read More
AUSTRALASIA
Extension of time for grace period in Australia
A 12 month “grace period” is provided in Australian Patent law, which allows any information made publicly available, with or without the consent of the applicant, the patentee, or...
A 12 month “grace period” is provided in Australian Patent law, which allows any information made publicly available, with...
Read More
AUSTRALASIA
IP-led recovery: putting COVID-19 in the rear-view mirror
There has been a steady decline in innovation in Australia since the Global Financial Crisis (GFC) in 2007. This is clear from the Australian Patent Office data which shows...
There has been a steady decline in innovation in Australia since the Global Financial Crisis (GFC) in 2007. This...
Read More
AUSTRALASIA
Names of Films – Trade Marks or Not Trade Marks?
LION In the recent Trade Marks Office decision of Long Way Home Holdings Pty Ltd v Saroo Brierly Enterprises Pty Ltd ATMO 109, the issue of whether a film...
LION In the recent Trade Marks Office decision of Long Way Home Holdings Pty Ltd v Saroo Brierly Enterprises Pty...
Read More
AUSTRALASIA
Brand Protection and Criminal Offences
As IP practitioners, you have probably noticed counterfeit watches being sold at local markets, sometimes hidden from immediate view by the seller.  Over the past ~30 years, growth in...
As IP practitioners, you have probably noticed counterfeit watches being sold at local markets, sometimes hidden from immediate view...
Read More
AUSTRALASIA
Australian Patent Office considers the plausibility of Swiss-style claims
Gliknik, Inc. v CSL Behring Lengnau AG  APO 46 (“Gliknik”) concerned a patent application for engineered proteins intended for use as replacements for intravenous immunoglobulin.  The application included claims...
Gliknik, Inc. v CSL Behring Lengnau AG  APO 46 (“Gliknik”) concerned a patent application for engineered proteins intended for...
Read More

Find Your Expert

Experts

Contact Us

Enquiries

Receive Insights

Subscribe